"The study adds to growing evidence that dupilumab, while highly effective for managing atopic dermatitis, may also be linked ...

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an update. CSPC Pharmaceutical Group has announced that its Dupilumab Injection, a biosimilar ...

The intervention being tested is Dupilumab, a drug administered via subcutaneous injection. It is intended to manage symptoms of PN, particularly the intense itching associated with the condition.

For nearly a decade, 71-year-old Ho Thian Kong struggled with the effects of chronic rhinosinusitis with nasal polyps, a ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Infants and young children with atopic dermatitis experienced improvements in signs and symptoms with dupilumab treatment regardless of other type 2 comorbidities, according to a study published ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, according to a ...

Dupilumab is undergoing Priority Review by the FDA as an add-on maintenance therapy for adults with uncontrolled COPD and type 2 inflammation, with a target action date of June 27, 2024, according ...

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...

One group got dupilumab, and the other placebo (but they kept using the inhalers). The dupilumab patients had an increased ability to exhale (4) as well as other improvements in lung function. In the ...

Dermatology > General Dermatology Dupilumab Gets First FDA-Approved Indication for Prurigo Nodularis — Significant improvement in itch and nodules at 24 weeks seen in two randomized trials by ...